Pfizer forecasts $54bn in 2022 sales from Covid-19 vaccine, treatment – with insight from The Wall Street Journal

While all the focus has been on the boom which Covid-19 brought to the tech sector, some other industries also benefitted massively from the pandemic. These rare birds are now searching for acquisitions to ensure their "once in an epoch opportunity" (to quote Pfizer's CEO) is turned to permanent advantage. Shipping companies have boomed as a result of the unprecedented global lockdown, with the cost of transporting containers going through the proverbial roof. For instance, the share price of JSE and Nasdaq-listed Grindrod Shipping is up five-fold since March 2020. Swollen bank balances have pushed shipping companies into takeover mode, with many even venturing outside their traditional circle of competence. A more obvious sector to benefit is Big Pharma. Vaccine-maker Pfizer's share price has more than doubled since the pandemic began, and the drug maker's revenue is set to pass a new barrier of $100bn this year (see story below). Like the shippers, Big Pharma is also hunting for places to invest the windfall. The big challenge for these winners – and their shareholders – will be resisting the temptation to overpay. Mining companies have taken over a decade to digest consequences of profligacy that followed the commodity boom to May 2008. The pandemic's nouveau riche would do well to study that experience. That's unlikely, though. Because, like the rest of us, they're only human. – Alec Hogg.Use Spotify? Access BizNews podcasts here..Use Apple Podcasts? Access BizNews podcasts here..___STEADY_PAYWALL___.Pfizer Forecasts $54bn in 2022 Sales from its Covid-19 Vaccine, Treatment.Drugmaker in search for deals to boost pipeline of products .By Jared Hopkins and Matt Grossman of The Wall Street Journal .As Pfizer Inc. forecasts strong sales this year for its Covid-19 vaccine and treatment, the drugmaker is on the hunt for deals to bolster its pipeline of experimental products..Pfizer said Tuesday that surging sales of its Covid-19 treatment and continued demand for its shots should boost the company's revenue to around $100 billion this year. The company estimated that sales of its antiviral pill Paxlovid will reach about $22 billion while the vaccine will add $32 billion..That is on top of last year's sales of $36.8 billion for the vaccine, also known as Comirnaty, the highest annual sales total for any pharmaceutical product. Paxlovid sales last year totaled $76 million..The company has done a handful of recent acquisitions and partnerships to bolster its pipeline of drugs and vaccines, including several partnerships announced last month to boost its growing mRNA business. In December, Pfizer said it would acquire Arena Pharmaceuticals Inc. ARNA 0.67% for $6.7 billion. Pfizer says it has invested $25 billion on business development since 2019..With a growing chest of cash, Pfizer says its deal-making strategy will focus on drugs in early and late-stage development in areas the company is already focusing on, such as oncology, immunology and rare diseases. The New York-based drugmaker forecasts new deals to generate $25 billion in additional revenue by 2030.."We would like to deploy capital in scientific areas that we have expertise in so we can choose the right targets," Chief Executive Albert Bourla said in an interview..The prospect of further deal making could address concerns from analysts and investors who are watching what Pfizer does with its windfall from the pandemic. Sales from the pandemic vaccine and treatment will taper over time and the company faces drops in sales as innovative products lose their patent protection..Pfizer's shares fell 2.8% on Tuesday. The drop was because investors were expecting Pfizer's guidance on this year's earnings per share to be higher than $6.35 to $6.55, according to Evercore ISI analyst Umer Raffat.."It's our all-time record high," Chief Financial Officer Frank D'Amelio said, regarding the company's guidance. He said analysts may have had higher expectations because of the pandemic products, but noted that Pfizer's estimates only include finalized agreements..Pfizer is in discussions with more than 100 countries for Paxlovid, so revenues are likely to come in higher than the $22 billion should it strike more agreements..Paxlovid is cleared for use in people in the U.S. 12 years and older who are at high risk of developing severe disease. The company said it expects to begin a study of the drug for children 6 years to 18 by the end of March. Results from studies of the drug in adults who are at standard risk for severe disease and household exposure should come later this year, Pfizer said..The drug remains in short supply, and has been difficult to find in the U.S., as Pfizer increases production to 120 million courses of treatment this year..While Pfizer says Paxlovid works safely, and was effective against the Omicron variant in laboratory studies, it says it is working on a new treatment, too. The potential drug is designed to counter possible viral resistance to Paxlovid, require fewer pills in a course, and to work without the aid of the antiviral ritonavir that is given with Paxlovid, but carries safety risks for patients taking some common medications, according to Pfizer.."We are not taking any chances; we're going to stay on the forefront of the scientific efforts to battle the pandemic," said Mr. Bourla..The company says it will begin studying the new Covid-19 treatment in the second half of this year..While Pfizer says demand for the vaccine may wane, it expects growing demand for the treatment. Yet sales of both will combine for more than half of annual $98 billion to $102 billion Pfizer forecasted revenue for 2022. Pfizer says the virus won't be fully eradicated in the near term because it is difficult to contain, has been shown to mutate, and that data shows natural infections don't lead to long-term protection needed to prevent transmission and mutations..The Covid-19 vaccine from Pfizer and partner BioNTech SE has grown into one of the most widely used shots globally. Pfizer's booster shots have also seen the greatest use in the U.S. Nearly 50 million have been administered..In the last three months of 2021, Pfizer's vaccine achieved $12.5 billion in sales, contributing to overall revenue of $23.84 billion. A year earlier, Pfizer's fourth-quarter revenue was $11.63 billion..Adjusted earnings grew to $1.08 a share, from 43 cents a share in the year-ago quarter. Analysts polled by FactSet had forecast adjusted earnings of 87 cents a share on sales of $24.16 billion.

Pfizer forecasts $54bn in 2022 sales from Covid-19 vaccine, treatment – with insight from The Wall Street Journal

Related Stories

Meet Tshepo Mahloele – Big Capitec shareholder, ABSIP’s “CEO of the Decade” now accused by Holomisa as kingpin of corrupt network

PREMIUM: Making of a great editor – the George Palmer playbook

Premium – BizNews global portfolio: ASML joins – so does Adobe as Bull takes hold again

Alec Hogg: Helen Zille predicts SA choice will be DA or EFF